Maternal RSV Vaccination and Nirsevimab Significantly Reduce Infant Hospitalizations and Infection Severity Under 6 Months

Maternal respiratory syncytial virus (RSV) vaccination and the monoclonal antibody nirsevimab significantly reduce infection and severity of RSV-related illness in infants under six months of age, according to a new study published in Contemporary Pediatrics.

The research, which analyzed real-world data from the 2024-2025 respiratory virus season, found that infants receiving either maternal RSV vaccination or nirsevimab after birth had substantially lower rates of RSV infection and healthcare utilization compared to unprotected infants.

These findings align with results from other recent studies examining RSV prevention strategies. A separate analysis published in JAMA Pediatrics estimated the effectiveness of maternal RSV immunization and nirsevimab against acute respiratory illness and their impact on RSV-associated hospitalizations during the same season.